Cargando…
Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells
Targeted pharmacologic activation of antigen-specific (AgS) T cells may bypass limitations inherent in current T cell-based cancer therapies. We describe two immunotherapeutics platforms for selective delivery of costimulatory ligands and peptide-HLA (pHLA) to AgS T cells. We engineered and deployed...
Autores principales: | Seidel, Ronald D., Merazga, Zohra, Thapa, Dharma Raj, Soriano, Jonathan, Spaulding, Emily, Vakkasoglu, Ahmet S., Ruthardt, Paige, Bautista, Wynona, Quayle, Steven N., Kiener, Peter A., Low, Simon, Ross, John F., Cemerski, Saso, Suri, Anish, Almo, Steven C., Chaparro, Rodolfo J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479091/ https://www.ncbi.nlm.nih.gov/pubmed/34584159 http://dx.doi.org/10.1038/s41598-021-98716-z |
Ejemplares similares
-
Human Vδ2 T Cells and Their Versatility for Immunotherapeutic Approaches
por: Sanz, Marta, et al.
Publicado: (2022) -
UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023) -
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
por: Carreño, Leandro J, et al.
Publicado: (2016) -
D-helix influences dimerization of the ATP-binding cassette (ABC) transporter associated with antigen processing 1 (TAP1) nucleotide-binding domain
por: Vakkasoglu, Ahmet S., et al.
Publicado: (2017) -
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)